ReviewJCO global oncology2022
Benefits of Adopting Hypofractionated Radiotherapy as a Standard of Care in Low-and Middle-Income Countries.
Review in JCO global oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Global perspective on implementing ultra-hypofractionated radiation therapy in breast cancer: a survey-based analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- From fractionation to financials: economic and clinical implications of hypofractionation in German outpatient radiotherapy practice.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Hypofractionated short course radiation therapy for recurrent ovarian cancer.Gynecologic oncology reports · 2026Article
- Is it time to say "shorter, safer, and smarter"?-interpreting early toxicity data from the PACE-C non-inferiority trial.Translational andrology and urology · 2026Article
- Hypofractionated radiotherapy in head and neck cancer: current evidence and future directions, with a focus on laryngeal cancer.Frontiers in oncology · 2026Review
- Hypofractionation Utilisation in Radiation Therapy: A Regional Department Evaluation.Journal of medical radiation sciences · 2025Article
- Radiotherapy boost to the primary tumour in locally advanced rectal cancer: Systematic review of practices andClinical and translational radiation oncology · 2025Review
- Article
- Improving Access to Radiotherapy in Gauteng: A Framework for Equitable Cancer Care.International journal of environmental research and public health · 2025Article
- A Feasibility Study for Clinical Implementation of hypo fractionated SBRT Program at a Clinic in an LMIC Using Locally Designed Lung Phantom.Advances in radiation oncology · 2025Article
- Article
- Assessing Radiology and Radiation Therapy Needs for Cancer Care in Low-and-Middle-Income Countries: Insight From a Global Survey of Departmental and Institutional Leaders.Advances in radiation oncology · 2024Article
- Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 3. Genitourinary and gynecological cancers.Radiation oncology journal · 2024Article
- Article
- Trends in Utilization and Medicare Spending on Short-Course Radiation Therapy for Breast and Prostate Cancer: An Episode-Based Analysis From 2015 to 2019.International journal of radiation oncology, biology, physics · 2024Article
- Review
- Review
- Cost-effectiveness of hypofractionated versus conventional fractionated radiotherapy for the treatment of men with early glottic cancer: a study in the Brazilian public and private health system.BMC health services research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.